The number of physic articles housebreaking the market has declined in the last decade. With the profitable downturn and increasing threat from generic companies, medicinal companies have never been under greater burden to develop new deviceful drugs. Many physic and biotechnology companies are now inquiring for efficacious strategies to improve hit-to-lead conversion and to separate futile compounds early in the evolution process. SMi's Drug Design colloquy will aim to address many of the challenging issues faced by the sedative crowd in drug design...

More: - Continued here